Investors

News & Press Release

  • 21.08.22

    Sisram Medical Ltd Announces 2022 Interim Results

  • 11.08.22

    Sisram Medical Ltd. to Hold First Half 2022 Financial Results Conference Call on August 22 at 8:30 a.m. ET

  • 28.06.22

    Sisram Medical’s associate company Tianjin JuveStar released Phase IIb result of lipolysis injection, reduction of submental fat by 15% through one treatment

  • 10.05.22

    LMNT, Sisram Medical’s Home-use Brand, is Officially Launching in China

  • 25.03.22

    Alma, a Sisram Medical Company, Announces the Launch of Alma TED™ and the Company’s Professional Skincare Line for the U.S. Market

  • 16.03.22

    Sisram Medical Ltd Announces 2021 Record Annual Results. Strong Performance Led by Synergistic Development of Four Main Business Lines Under One Ecosystem.

  • 09.01.22

    Sisram Medical has Increased the Shares by the Controlling Shareholder Fosun Pharma, Demonstrating Shareholder’s Strong Confidence

  • 14.09.21

    Alma Hybrid Platform by Alma, a Sisram Medical company, Wins 2021 Gold Award for Industrial and Life Science Medical/Scientific Machinery Design

  • 22.08.21

    Sisram Medical Ltd, Announces Its Interim Results for the First Half of 2021 Demonstrating an Impressive Performance Led by Global Business Expansion and R&D Breakthroughs

  • 15.07.21

    Sisram Medical (1696.HK) and Fosun Industrial Enter into a Sublicense Agreement for the Commercialization of DaxibotulinumtoxinA (RT002) Injectable

52 week Range -
/